News | December 19, 2018

Silence Therapeutics Advances Next RNAi Medicine

Lipoprotein(a) targeting, an exciting approach to address cardiovascular disease

LONDON, Silence Therapeutics, PLC (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announcesthe addition of a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease.

The product candidate, SLN360,silences apolipoprotein (a), a component of lipoprotein(a) (“LP(a)”), which is a highly validated target based on extensive human genetic data. Elevated LP(a) levels have been associated with increased risk of cardiovascular disease, independent of additional risk factors.

Data generated in non-human primates show that Silence’s proprietary GalNAc-siRNA candidate SLN360 yields potent and durable serum LP(a) knockdown for over six weeks following a low single dose, with higher doses resulting in sustained knockdown (>90%) for at least two months with no trend back to baseline levels observed. These performance data, together with the subcutaneous administration route and safety profile of our molecules, support an infrequent and patient-friendly dosing regimen. The IND/CTA for SLN360 is anticipated to be filed in the second half of 2020.

David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:
“We are excited to add SLN360, our new LP(a) targeting siRNA medicine, to our pipeline of wholly owned assets aimed at addressing areas of significant unmet need. High LP(a) levels in humans increase the probability of significant cardiovascular disease and lowering these levels is associated with reducing cardiovascular risks and disease. Our data suggest that SLN360 significantly reduces serum LP(a) in nonhuman primates for up to two months and ultimately will use patient convenient sub-cutaneous dosing. We are poised to advance SLN360 towards the clinic as a new medicine for patients with significant cardiovascular risk. “

David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented: “We are excited to add SLN360, our new LP(a) targeting siRNA medicine, to our pipeline of wholly owned assets aimed at addressing areas of significant unmet need. High LP(a) levels in humans increase the probability of significant cardiovascular disease and lowering these levels is associated with reducing cardiovascular risks and disease. Our data suggest that SLN360 significantly reduces serum LP(a) in nonhuman primates for up to two months and ultimately will use patient convenient sub-cutaneous dosing. We are poised to advance SLN360 towards the clinic as a new medicine for patients with significant cardiovascular risk."

SOURCE: Silence Therapeutics plc